Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hayato Yamazaki

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Modern Rheumatology|November 17, 2016
Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in JapanHayato Yamazaki, Fumio Hirano, Tsutomu Takeuchi, et al.
Rheumatology International|May 24, 2014
The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) databaseRyoko Sakai, Soo-Kyung Cho, Toshihiro Nanki, et al.
Modern Rheumatology|December 16, 2014
Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumoniaMichi Tanaka, Ryuji Koike, Ryoko Sakai, et al.
Modern Rheumatology|December 7, 2016
Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategyFumio Hirano, Waka Yokoyama, Hayato Yamazaki, et al.
Modern Rheumatology|December 11, 2013
A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and JapanSoo-Kyung Cho, Ryoko Sakai, Toshihiro Nanki, et al.
Arthritis Research & Therapy|April 17, 2015
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registryRyoko Sakai, Soo-Kyung Cho, Toshihiro Nanki, et al.
The Journal of Rheumatology|February 3, 2015
Assessment of risks of pulmonary infection during 12 months following immunosuppressive treatment for active connective tissue diseases: a large-scale prospective cohort studyHayato Yamazaki, Ryoko Sakai, Ryuji Koike, et al.
Arthritis Research & Therapy|January 20, 2017
Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trialMasako Utsunomiya, Hiroaki Dobashi, Toshio Odani, et al.
Rheumatology Advances in Practice|November 2, 2020
An open-label, randomized controlled trial of sulfamethoxazole-trimethoprim for <i>Pneumocystis</i> prophylaxis: results of 52-week follow-upMasako Utsunomiya, Hiroaki Dobashi, Toshio Odani, et al.
Annals of the Rheumatic Diseases|April 17, 2012
Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target moleculesRyoko Sakai, Michi Tanaka, Toshihiro Nanki, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Modern Rheumatology|November 17, 2016
Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in JapanHayato Yamazaki, Fumio Hirano, Tsutomu Takeuchi, et al.
Rheumatology International|May 24, 2014
The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) databaseRyoko Sakai, Soo-Kyung Cho, Toshihiro Nanki, et al.
Modern Rheumatology|December 16, 2014
Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumoniaMichi Tanaka, Ryuji Koike, Ryoko Sakai, et al.
Modern Rheumatology|December 7, 2016
Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategyFumio Hirano, Waka Yokoyama, Hayato Yamazaki, et al.
Modern Rheumatology|December 11, 2013
A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and JapanSoo-Kyung Cho, Ryoko Sakai, Toshihiro Nanki, et al.
Arthritis Research & Therapy|April 17, 2015
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registryRyoko Sakai, Soo-Kyung Cho, Toshihiro Nanki, et al.
The Journal of Rheumatology|February 3, 2015
Assessment of risks of pulmonary infection during 12 months following immunosuppressive treatment for active connective tissue diseases: a large-scale prospective cohort studyHayato Yamazaki, Ryoko Sakai, Ryuji Koike, et al.
Arthritis Research & Therapy|January 20, 2017
Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trialMasako Utsunomiya, Hiroaki Dobashi, Toshio Odani, et al.
Rheumatology Advances in Practice|November 2, 2020
An open-label, randomized controlled trial of sulfamethoxazole-trimethoprim for <i>Pneumocystis</i> prophylaxis: results of 52-week follow-upMasako Utsunomiya, Hiroaki Dobashi, Toshio Odani, et al.
Annals of the Rheumatic Diseases|April 17, 2012
Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target moleculesRyoko Sakai, Michi Tanaka, Toshihiro Nanki, et al.
Pageof 2